A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2015
At a glance
- Drugs RV 1729 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors RespiVert
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.